Paying users zone. Data is covered by .

  • Get to Bristol-Myers Squibb Co. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

 

$15.99


Ratios (Summary)

Bristol-Myers Squibb Co., liquidity ratios

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Current ratio
Quick ratio
Cash ratio

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

Ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Bristol-Myers Squibb Co.'s current ratio improved from 2015 to 2016 and from 2016 to 2017.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Bristol-Myers Squibb Co.'s quick ratio improved from 2015 to 2016 and from 2016 to 2017.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Bristol-Myers Squibb Co.'s cash ratio improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017.

Top


Current Ratio

Bristol-Myers Squibb Co., current ratio calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Current assets
Current liabilities
Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Current Ratio, Sector
Pharmaceuticals & Biotechnology
Current Ratio, Industry
Health Care

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

2017 Calculations

1 Current ratio = Current assets ÷ Current liabilities
= ÷ =

Ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Bristol-Myers Squibb Co.'s current ratio improved from 2015 to 2016 and from 2016 to 2017.

Top


Quick Ratio

Bristol-Myers Squibb Co., quick ratio calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Cash and cash equivalents
Marketable securities
Net trade receivables
Alliance receivables
Royalties, VAT and other
Total quick assets
Current liabilities
Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Quick Ratio, Sector
Pharmaceuticals & Biotechnology
Quick Ratio, Industry
Health Care

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

2017 Calculations

1 Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

Ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Bristol-Myers Squibb Co.'s quick ratio improved from 2015 to 2016 and from 2016 to 2017.

Top


Cash Ratio

Bristol-Myers Squibb Co., cash ratio calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Cash and cash equivalents
Marketable securities
Total cash assets
Current liabilities
Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Cash Ratio, Sector
Pharmaceuticals & Biotechnology
Cash Ratio, Industry
Health Care

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

2017 Calculations

1 Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

Ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Bristol-Myers Squibb Co.'s cash ratio improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017.

Top